Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;39(10):1951-1953.
doi: 10.1007/s11606-024-08829-0. Epub 2024 May 28.

National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021

Chase L Barham  1 , Andrea E Strahan  2 , Kun Zhang  2 , Gery P Guy Jr  2
Affiliations

National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021

Chase L Barham et al. J Gen Intern Med. 2024 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Figure 1
Figure 1
A Individuals dispensed buprenorphine per individual with opioid use disorder (OUD) — United States, 2019. B Percent change in total days of buprenorphine dispensed per capita, by state — United States, 2019–2021. Notes: A Nationally, mean number of individuals dispensed buprenorphine per individual was 0.18 in 2019; state-wide variation ranged from a minimum of 0.04 to a maximum of 0.46. Data on the number of individuals dispensed a buprenorphine prescription are from projected IQVIA Longitudinal Prescription (LRx) data, 2019. IQVIA custom projected Longitudinal Prescription (LRx) data for state estimates with 100% retail pharmacy coverage. Data on 2019 adjusted opioid use disorder prevalence estimates are from Krawczyk et al. (2022) (multipliers were only available for 2019 data). State data are divided into quartiles. B Total days’ supply (sum of days supplied) per capita was used to capture state-level changes in dispensing per person (both the number of prescriptions and the length prescribed). Data on buprenorphine prescriptions dispensed and days supplied are from IQVIA Xponent 2021, extracted 2023. IQVIA collected all-payer pharmaceutical data from approximately 48,900 US retail pharmacies and projected data for state estimates with 100% retail pharmacy coverage. Population estimates are from the US Census Bureau. Population and Housing Unit Estimates (https://www.census.gov/programs-surveys/popest/data/data-sets.html). State data are divided into quartiles.
See this image and copyright information in PMC

References

    1. Spencer MR, Miniño AM, Warner M. Drug overdose deaths in the United States, 2001–2021. NCHS Data Brief, no 457. Hyattsville, MD: National Center for Health Statistics. 2022. 10.15620/cdc:122556.
    1. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137-145. 10.7326/M17-3107. 10.7326/M17-3107 - DOI - PMC - PubMed
    1. Cremer LJ, Board A, Guy Jr GP, Schieber L, Asher A, Parker EM. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex–United States, March 2019–December 2020. Drug Alcohol Depend. 2022 ;232:109192. 10.1016/j.drugalcdep.2021.109192 - DOI - PMC - PubMed
    1. Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022:103786. 10.1016/j.drugpo.2022.103786 - PMC - PubMed
    1. Population and Housing Unit Estimates. US Census Bureau. 2022. https://www.census.gov/programs-surveys/popest.html. Accessed 06/20/2022.

LinkOut - more resources